Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01409148 · ClinicalTrials.gov registry record · Phase 1
Radioimmunoimaging of AL Amyloidosis
A Phase 1 study of AL Amyloidosis, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT01409148 is a Phase 1 study of AL Amyloidosis that has completed, run by University of Tennessee. The registered enrollment target is 38 participants, below the 422-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01409148, a Phase 1 study of AL Amyloidosis, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
Conditions Studied
Interventions
- BIOLOGICAL 124I-labeled monoclonal antibody Mu 11-1F4
Study Locations (1)
Tennessee
- University of Tennessee Medical Center - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01409148
The ClinicalTrials.gov registry entry for NCT01409148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 422-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (91% lower). The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AL Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which 124I-labeled monoclonal antibody Mu 11-1F4 is the first listed.
NCT01409148 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT01409148 about?
NCT01409148 is a clinical study titled "Radioimmunoimaging of AL Amyloidosis". The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
What is the current status of trial NCT01409148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2008-11. Estimated completion is 2012-03.
What conditions does trial NCT01409148 study?
This clinical trial studies the following conditions: AL Amyloidosis.
What interventions are being tested in trial NCT01409148?
The interventions under investigation include: 124I-labeled monoclonal antibody Mu 11-1F4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01409148?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01409148 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
RECRUITING · Phase 1
-
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 1
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.